Agomab Therapeutics

Agomab Therapeutics

Founded in 2017 in Ghent, Belgium, Agomab Therapeutics emerged from the laboratory of Professor Paulina Wosik at the University of Antwerp, who identified the MET receptor as a master switch for tissue repair. Tim Knotnerus, a veteran of Galapagos NV's fibrosis programs, assumed the CEO role to translate this biology into a pipeline anchored by AGMB-129, an oral small-molecule MET agonist originally developed by Pfizer and shelved after an oncology indication failed. Agomab's thesis departs from the typical anti-inflammatory approach in chronic disease, instead pursuing structural repair in damaged organs. The firm's pipeline strategy is concentrated around the MET pathway. Lead candidate AGMB-129 targets fibrostenosing Crohn's disease, a severe form where intestinal scarring obstructs digestion and for which no approved therapy exists beyond surgery — the Phase 2a STENOVA trial completed enrollment in January 2024 (per the firm, 2024). A second candidate, AGMB-447, is an inhaled formulation designed to stimulate lung epithelial repair in idiopathic pulmonary fibrosis, a disease with a five-year survival rate worse than most cancers and currently addressed only by drugs that modestly slow decline. Agomab has also explored MET agonism in liver fibrosis and acute organ injury, maintaining a single-pathway, multi-indication logic. Two existing IPF drugs — Esbriet and Ofev — generated roughly $4 billion combined globally in 2023, establishing a pricing benchmark for novel mechanisms (per Evaluate Pharma, 2024). Agomab's co-investors include Pontifax Venture Capital, Cormorant Asset Management, and Redmile Group, who joined a $74 million Series A in 2021 and later participated in a $100 million Series B round in 2023 that extended the firm's cash runway through the Crohn's Phase 2 readout. The company operates from a single site in Ghent, leveraging Belgium's favorable R&D tax framework and proximity to the European Medicines Agency. As of the Series B close, the team numbered roughly 40, weighted toward clinical operations and translational biology. The firm has disclosed no adjacent vehicles, incubators, or philanthropic arms; it operates as a pure-play biotech with a venture capital syndicate backing rather than a single-family-office structure. In January 2024, Agomab reported completion of enrollment for the STENOVA trial, and the firm expects to report Phase 2a data by the first half of 2026 — a binary catalyst that will determine whether the MET agonism mechanism translates beyond preclinical models (per the firm's clinical trial disclosures, 2024). The structural differentiator is Agomab's narrow pathway focus: rather than building a broad, risk-diversified portfolio, the firm bets that a single mechanism can address multiple high-mortality fibrotic diseases. This concentration risk is paired with an unusual asset-origin story — the lead molecule was abandoned by a larger pharmaceutical company for a different indication, then repurposed with a novel clinical endpoint. In an era when biotechs often compete for incremental improvements against standard-of-care, Agomab is attempting to create a new treatment class for conditions where no disease-modifying drug has ever reached market.